Novel fluoro-substituted benzo- and benzothieno fused pyrano[2,3-c]pyrazol-4(1H)-ones
作者:Wolfgang Holzer、Angelika Ebner、Karin Schalle、Gyselle Batezila、Gernot A. Eller
DOI:10.1016/j.jfluchem.2010.07.007
日期:2010.10
A straightforward, two-step synthesis of fluoro substituted chromeno[2,3-c]pyrazol- and [1]benzothieno[2′,3′:5,6]pyrano[2,3-c]pyrazol-4(1H)-ones, respectively, is presented. Hence, treatment of 1-substituted or 1,3-disubstituted 2-pyrazolin-5-ones with fluoro substituted 2-fluorobenzoyl chlorides or 3-chloro-6-fluoro-1-benzothiophene-2-carbonyl chloride using calcium hydroxide in refluxing 1,4-dioxane
氟取代铬诺[2,3- c ]吡唑-和[1]苯并噻吩诺[2',3':5,6]吡喃[2,3 - c ]吡唑-4(1 H)的简单,两步合成)-一个,分别。因此,在回流条件下,使用氢氧化钙1用氟取代的2-氟苯甲酰氯或3-氯-6-氟-1-苯并噻吩-2-羰基氯处理1-取代或1,3-二取代的2-吡唑啉-5-酮。 ,4-二恶烷得到相应的4-芳酰基吡唑-5-醇,将其环化成稠环系统。通过用三氟乙酸处理1-(4-甲氧基苄基)保护的同类物,获得了5-氟铬诺[2,3- c ]吡唑-4(1 H)-。5-氟铬诺[2,3 - c ]吡唑-4(1)的处理用甲基肼得到的H)-酮提供了新颖的四环体系,例如2-甲基-7-苯基-2,7-二氢吡唑并[4',3':5,6]吡喃并[4,3,2- cd ]吲唑。对获得的化合物进行了详细的NMR光谱研究(1 H,13 C,15 N,19 F)。
[EN] PYRAZOLONE DERIVATIVES AS NITROXYL DONORS<br/>[FR] DÉRIVÉS DE PYRAZOLONE UTILISÉS EN TANT QUE DONNEURS DE NITROXYLE
申请人:CARDIOXYL PHARMACEUTICALS INC
公开号:WO2015183839A1
公开(公告)日:2015-12-03
The disclosed subject matter provides pyrazolone derivative compounds, pharmaceutical compositions comprising such compounds, kits comprising such compounds, and methods of using such compounds or pharmaceutical compositions. In particular, the disclosed subject matter provides methods of using such compounds or pharmaceutical compositions for treating heart failure.
An Efficient Approach to Heterocyclic Analogues of Xanthone: A Short Synthesis of All Possible Pyrido[5,6]pyrano[2,3-<i>c</i>]pyrazol-4(1<i>H</i>)-ones
An efficient and generally applicable synthesis of various [5,6]pyrano[2,3-c]pyrazol-4(1H)-ones by the reaction of either 1-substituted or 1,3-disubstituted 2-pyrazolin-5-ones with different o-halopyridinecarbonyl chlorides or with 3-chloroquinoline-2-carbonyl chloride, using calcium hydroxide in 1,4-dioxane, is described. In the course of the preparation of pyrazolo[4′,3′:5,6]pyrano[2,3-c]pyridin-4(1H)-ones, the intermediate 4-(3-chloroisonicotinoyl)-1H-pyrazol-5-ols did not cyclize spontaneously and thus were transformed into the corresponding tricycles by treatment with NaH in DMF. The N1-unsubstituted title compounds were obtained upon treatment of the corresponding 1-(4-methoxybenzyl) protected congeners with trifluoroacetic acid.
2-(Pyrazol-5-yl-oxymethyl)-1,2-benzisothiazol-3(2H)-one 1,1-dioxides, pharmaceutical compositions containing them and methods for the treatment of degenerative diseases utilizing them.